PKAN — Pantothenate Kinase-Associated Neurodegeneration

PKAN — Pantothenate Kinase-Associated Neurodegeneration

Overview

PKAN (Pantothenate Kinase-Associated Neurodegeneration) is the most common form of NBIA (Neurodegeneration with Brain Iron Accumulation), accounting for 35-50% of all cases. It is caused by autosomal recessive mutations in the [PANK2](/entities/pank2) gene (pantothenate kinase 2), which catalyzes the rate-limiting first step of coenzyme A (CoA) biosynthesis. The resulting CoA deficiency causes mitochondrial dysfunction, impaired fatty acid metabolism, and characteristic iron accumulation in the globus pallidus — visible as the pathognomonic "eye of the tiger" sign on MRI[@zhou2020][@hoglinger2021].

Genetics and Inheritance

| Feature | Detail |
|---------|--------|
| Gene | PANK2 (Pantothenate Kinase 2) on chromosome 17p11.2 |
| Inheritance | Autosomal recessive |
| Mutation spectrum | Missense (late-onset), nonsense/frameshift (classic/early-onset) |
| Protein | Pantothenate kinase 2 (mitochondrial matrix enzyme) |
| Substrate | Vitamin B5 (pantothenate) → phosphopantothenate |

PANK2 is a mitochondrial matrix enzyme that catalyzes the phosphorylation of pantothenate (vitamin B5) to phosphopantothenate — the first and rate-limiting step of the five-step CoA biosynthesis pathway. Patients with classic PKAN typically have complete or near-complete loss of PANK2 activity, while late-onset forms retain partial activity.

Molecular Mechanism

```mermaid
flowchart TD
A["PANK2 Biallelic Mutation"] --> B["Loss of Pantothenate Kinase 2 Activity"]

PKAN — Pantothenate Kinase-Associated Neurodegeneration

Overview

PKAN (Pantothenate Kinase-Associated Neurodegeneration) is the most common form of NBIA (Neurodegeneration with Brain Iron Accumulation), accounting for 35-50% of all cases. It is caused by autosomal recessive mutations in the [PANK2](/entities/pank2) gene (pantothenate kinase 2), which catalyzes the rate-limiting first step of coenzyme A (CoA) biosynthesis. The resulting CoA deficiency causes mitochondrial dysfunction, impaired fatty acid metabolism, and characteristic iron accumulation in the globus pallidus — visible as the pathognomonic "eye of the tiger" sign on MRI[@zhou2020][@hoglinger2021].

Genetics and Inheritance

| Feature | Detail |
|---------|--------|
| Gene | PANK2 (Pantothenate Kinase 2) on chromosome 17p11.2 |
| Inheritance | Autosomal recessive |
| Mutation spectrum | Missense (late-onset), nonsense/frameshift (classic/early-onset) |
| Protein | Pantothenate kinase 2 (mitochondrial matrix enzyme) |
| Substrate | Vitamin B5 (pantothenate) → phosphopantothenate |

PANK2 is a mitochondrial matrix enzyme that catalyzes the phosphorylation of pantothenate (vitamin B5) to phosphopantothenate — the first and rate-limiting step of the five-step CoA biosynthesis pathway. Patients with classic PKAN typically have complete or near-complete loss of PANK2 activity, while late-onset forms retain partial activity.

Molecular Mechanism

CoA Biosynthesis Pathway

CoA is synthesized in five enzymatic steps:

PANK2 deficiency blocks the first step, causing 50-90% reduction in cellular CoA in affected tissues[@leonardi2019].

Why the Globus Pallidus?

The globus pallidus internus (GPi) and substantia nigra pars reticulata (SNr) are preferentially vulnerable in PKAN because:

• Highest neuronal energy demand in the basal ganglia
• High iron content relative to other brain regions
• GABAergic neurons with high mitochondrial density — most sensitive to CoA deficit
• Progressive neuronal death in these regions causes the characteristic movement disorder

The "Eye of the Tiger" Sign

The MRI finding of central T2 hyperintensity surrounded by T2 hypointensity in the GP reflects:

• Central zone: glial reaction and tissue vacuolization
• Peripheral zone: iron deposition (hemosiderin)
• This pattern appears early and is highly specific for PKAN among NBIA subtypes

Clinical Presentation

| Feature | Classic PKAN | Atypical/Late-Onset PKAN |
|---------|-------------|--------------------------|
| Age of onset | 3-12 years | Adolescence to adulthood |
| Initial symptoms | Gait disorder, dystonia | Dystonia, dysarthria, gait difficulties |
| Progression | Rapid (loss of ambulation in 5-10 years) | Slower (15+ years to disability) |
| Eye of the tiger | Usually present | Often absent or subtle |
| Retinitis pigmentosa | Common | Less common |
| Pyramidal signs | Common | Variable |
| Cognitive decline | Progressive | Mild-to-moderate |

Therapeutic Approaches

Current Approaches

| Approach | Status | Evidence |
|----------|--------|----------|
| Pantethine (vitamin B5 derivative) | Active trials | Bypasses defective PANK2; some benefit in late-onset[@collins2022] |
| Phosphopantetheine (PPE) | Investigational | Directly replaces the product of the PANK2 step[@patel2024] |
| CoA supplementation | Limited | CoA does not cross BBB efficiently |
| Deep brain stimulation (DBS) | Used for severe dystonia | GPi-DBS shows benefit in selected cases |
| Iron chelation | Not standard | Iron is secondary; clinical benefit unclear |
| Physical/occupational therapy | Standard of care | Maintains function |

Emerging Research

• PANTOPAN study (NCT05194109): Phosphopantetheine supplementation trial
• AAV-PANK2 gene therapy: Preclinical studies in mouse models
• Small molecule PANK2 activators: Compounds to enhance residual enzyme activity
• CoA prodrugs with BBB penetration: Designed to restore CNS CoA levels

Therapeutic Rationale

Unlike other neurodegenerative disorders where iron accumulation is primary, PKAN patients may benefit from metabolic supplementation because the upstream block (pantothenate → phosphopantothenate) is bypassable with downstream intermediates. This makes PKAN a uniquely treatable NBIA subtype.

Cross-Links

• [NBIA Overview](/diseases/nbia)
• [MPAN Pathway](/mechanisms/mitochondrial-membrane-protein-associated-neurodegeneration-mpan)
• [BPAN Pathway](/mechanisms/beta-propeller-protein-associated-neurodegeneration-bpan)
• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction-comparison)
• [Iron Metabolism in Neurodegeneration](/mechanisms/metal-dyshomeostasis-comparison)
• [Dystonia Mechanisms](/mechanisms/dystonia-mechanisms)
• [PANK2 Gene](/entities/pank2) (when created)
• [CoA Biosynthesis](/mechanisms/coa-biosynthesis-pathway) (when created)

References